GS-9901 is a potent, orally bioavailable and highly selective inhibitor of PI3Kδ (PI3Kdelta IC50 = 1.0nM, HWB delta EC50 = 1.5 nM; CLpr hHep = 0.05 L/h/kg.). GS-9901 exhibits an excellent pharmacokinetic profile and is efficacious in a rodent model of rheumatoid arthritis. GS-9901 displays efficacy in a rat model of arthritis and is predicted to be suitable for q.d. dosing in humans. The favorable in vitro and in vivo attributes of GS-9901 resulted in its selection as a development candidate. References: Patel L, Chandrasekhar J, Evarts J, Forseth K, Haran AC, Ip C, Kashishian A, Kim M, Koditek D, Koppenol S, Lad L, Lepist EI, McGrath ME, Perreault S, Puri KD, Villasenor AG, Somoza JR, Steiner BH, Therrien J, Treiberg J, Phillips G. Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability. J Med Chem. 2016 Oct 3. [Epub ahead of print] PubMed PMID: 27660855.

纯度：≥98%

CAS：1640247-87-5